EMMAC Life Sciences Group Novel Foods Application Validated in UK and EU

27th April 2021

Europe’s largest vertically integrated medical cannabis company, EMMAC Life Sciences Group, has gained validation from both the UK Food Standards Agency and the EU Food Safety Authority for its dossier on nature-identical CBD as a Novel Food.

The UK FSA has included in its updated Public List a number of EMMAC’s CBD products that are used in Blossom, MYO, and Canidol brands. All of these brands are manufactured by Rokshaw, EMMAC’s wholly-owned subsidiary.

CBD companies in the UK that have been active since the 13th of February 2020 were able to submit a Novel Foods application by the end of March, 2021. Only brands that have received validation from the FSA will be permitted to remain on sale in the UK. The FSA plans to update its Public List of products linked to a validated Novel Foods application on a weekly basis.

In a statement given on receiving its CBD brands validation, EMMAC CEO Antonio Costanzo, said:

“We are delighted that Rokshaw is one of the first companies to have its CBD branded products approved by the FSA. EMMAC, and by extension Rokshaw, has always been science-led and customer-centric.

“The FSA’s validation is an important milestone because it is another proof point that gives our customers peace of mind that they are purchasing safe and high-quality products. I’m proud of our team’s work in securing the legal requirement so quickly and advancing our position in the wellness market across the UK.”

About EMMAC Life Sciences Group

EMMAC Life Sciences Group (EMMAC) is the largest vertically integrated cannabis company in Europe, bringing together pioneering science and research with cutting-edge cultivation, extraction, and production. The company has developed a unique supply and distribution network throughout Europe with a vision to bring the life-enhancing potential of cannabis to those that need it.
EMMAC was this month acquired by Curaleaf – the leading US provider of consumer products in cannabis.

Related Stories